A Trial of Gemcitabine, Pembrolizumab and IMM-101 as First Line Treatment in Patients With Metastatic Pancreatic Cancer
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- David Chang
University of Glasgow
Study Chair - Jeff Evans
University of Glasgow
Study Chair
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
6 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- University Hospitals Bristol Nhs Foundation Trust
Bristol, United Kingdom
- University Hospitals Coventry & Warwickshire
Coventry, United Kingdom
- Beatson West of Scotland Cancer Centre
Glasgow, United Kingdom
- Royal Free London Hospital
London, United Kingdom
- Royal Marsden Hospital
London, United Kingdom
- the Christie Hospital
Manchester, United Kingdom
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 17 Jun 2024
- Primary completion
- 23 May 2025
- Completion
- 23 May 2025
- Last update posted
- 11 Jul 2025
- Registered enrollment
- 0
- Registry id
- NCT06498518
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.